Sarcoidosis: Drugs under Investigation

Jonas Christian Schupp; Björn Christian Frye; Gernot Zissel; Joachim Müller-Quernheim

doi:10.1055/s-0037-1603768

Seminars in Respiratory and Critical Care Medicine, Inhaltsverzeichnis

Semin Respir Crit Care Med 2017; 38(04): 532-537
DOI: 10.1055/s-0037-1603768

Review Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Sarcoidosis: Drugs under Investigation

Jonas Christian Schupp

¹Department of Pneumology, Medical Center - University of Freiburg, Medical Faculty, University of Freiburg, Germany

²Section of Pulmonary, Critical Care and Sleep Medicine, Yale University School of Medicine, New Haven, Connecticut

,

Björn Christian Frye

¹Department of Pneumology, Medical Center - University of Freiburg, Medical Faculty, University of Freiburg, Germany

,

Gernot Zissel

¹Department of Pneumology, Medical Center - University of Freiburg, Medical Faculty, University of Freiburg, Germany

,

Joachim Müller-Quernheim

¹Department of Pneumology, Medical Center - University of Freiburg, Medical Faculty, University of Freiburg, Germany

› Institutsangaben

Abstract

Etiology of sarcoidosis is still elusive, yet there has been considerable progress in various areas of basic and clinical research. In this review, we focus on ongoing or recently completed clinical–pharmacological studies in patients with sarcoidosis. Positive studies were published in well-characterized and homogenous subcohorts of sarcoid patients. Several drugs have shown a positive effect on sarcoidosis-associated fatigue, cutaneous sarcoidosis, and pulmonary hypertension in sarcoid patients. It seems that the recruitment of clinically precisely defined subcohorts is necessary to achieve positive outcomes in studies on sarcoidosis.

Keywords

sarcoidosis - drugs - clinical trials - review - treatment - human

Volltext

Referenzen

References
1 Drent M, Lower EE, De Vries J. Sarcoidosis-associated fatigue. Eur Respir J 2012; 40 (01) 255-263
2 Lower EE, Malhotra A, Surdulescu V, Baughman RP. Armodafinil for sarcoidosis-associated fatigue: a double-blind, placebo-controlled, crossover trial. J Pain Symptom Manage 2013; 45 (02) 159-169
3 Lower EE, Harman S, Baughman RP. Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue. Chest 2008; 133 (05) 1189-1195
4 Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet PY, Müller-Quernheim J. Sarcoidosis. Lancet 2014; 383 (9923): 1155-1167
5 Baughman RP, Strohofer SA, Buchsbaum J, Lower EE. Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis. J Lab Clin Med 1990; 115 (01) 36-42
6 Baughman RP, Judson MA, Ingledue R, Craft NL, Lower EE. Efficacy and safety of apremilast in chronic cutaneous sarcoidosis. Arch Dermatol 2012; 148 (02) 262-264
7 Pariser RJ, Paul J, Hirano S, Torosky C, Smith M. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol 2013; 68 (05) 765-773
8 Brines M, Dunne AN, van Velzen M. , et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol Med 2015; 20 (01) 658-666
9 Heij L, Niesters M, Swartjes M. , et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Mol Med 2012; 18: 1430-1436
10 Dahan A, Dunne A, Swartjes M. , et al. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. Mol Med 2013; 19: 334-345
11 Baughman RP, Culver DA, Cordova FC. , et al. Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial. Chest 2014; 145 (04) 810-817
12 Judson MA, Highland KB, Kwon S. , et al. Ambrisentan for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28 (02) 139-145
13 Judson MA, Baughman RP, Costabel U. , et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur Respir J 2014; 44 (05) 1296-1307
14 Diaz-Guzman E, Farver C, Parambil J, Culver DA. Pulmonary hypertension caused by sarcoidosis. Clin Chest Med 2008; 29 (03) 549-563 , x
15 Ford HJ, Baughman RP, Aris R, Tilley SL, Engel P, Donohue JF. Tadalafil for sarcoidosis associated pulmonary hypertension. Am J Respir Crit Care Med 2014; 189: A4798
16 Droitcourt C, Rybojad M, Porcher R. , et al. A randomized, investigator-masked, double-blind, placebo-controlled trial on thalidomide in severe cutaneous sarcoidosis. Chest 2014; 146 (04) 1046
17 Müller-Quernheim J, Saltini C, Sondermeyer P, Crystal RG. Compartmentalized activation of the interleukin 2 gene by lung T lymphocytes in active pulmonary sarcoidosis. J Immunol 1986; 137 (11) 3475-3483
18 Hunninghake GW, Crystal RG. Mechanisms of hypergammaglobulinemia in pulmonary sarcoidosis. Site of increased antibody production and role of T lymphocytes. J Clin Invest 1981; 67 (01) 86-92
19 Sweiss NJ, Lower EE, Mirsaeidi M. , et al. Rituximab in the treatment of refractory pulmonary sarcoidosis. Eur Respir J 2014; 43 (05) 1525-1528
20 Jawad S, Liu B, Agron E, Nussenblatt RB, Sen HN. Elevated serum levels of interleukin-17A in uveitis patients. Ocul Immunol Inflamm 2013; 21 (06) 434-439
21 Dick AD, Tugal-Tutkun I, Foster S. , et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology 2013; 120 (04) 777-787
22 Letko E, Yeh S, Foster CS, Pleyer U, Brigell M, Grosskreutz CL. ; AIN457A2208 Study Group. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy. Ophthalmology 2015; 122 (05) 939-948
23 Maya JR, Sadiq MA, Zapata LJ. , et al. Emerging therapies for noninfectious uveitis: what may be coming to the clinics. J Ophthalmol 2014; 2014: 310329
24 Dalm VA, van Hagen PM, Krenning EP. The role of octreotide scintigraphy in rheumatoid arthritis and sarcoidosis. Q J Nucl Med 2003; 47 (04) 270-278
25 Gettig J, Cummings JP, Matuszewski K. H.p. Acthar gel and cosyntropin review: clinical and financial implications. P T 2009; 34 (05) 250-257
26 Drake WP, Dhason MS, Nadaf M. , et al. Cellular recognition of Mycobacterium tuberculosis ESAT-6 and KatG peptides in systemic sarcoidosis. Infect Immun 2007; 75 (01) 527-530
27 Allen SS, Evans W, Carlisle J. , et al. Superoxide dismutase A antigens derived from molecular analysis of sarcoidosis granulomas elicit systemic Th-1 immune responses. Respir Res 2008; 9: 36
28 Drake WP, Richmond BW, Oswald-Richter K. , et al. Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2013; 30 (03) 201-211
29 Palinski W. Immunomodulation: a new role for statins?. Nat Med 2000; 6 (12) 1311-1312
30 Siepmann K, Huber M, Stübiger N, Deuter C, Zierhut M. Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis : a retrospective analysis of 106 patients. Graefes Arch Clin Exp Ophthalmol 2006; 244 (07) 788-794
31 Buenestado A, Grassin-Delyle S, Guitard F. , et al. Roflumilast inhibits the release of chemokines and TNF-α from human lung macrophages stimulated with lipopolysaccharide. Br J Pharmacol 2012; 165 (06) 1877-1890
32 Julian MW, Shao G, Schlesinger LS. , et al. Nicotine treatment improves Toll-like receptor 2 and Toll-like receptor 9 responsiveness in active pulmonary sarcoidosis. Chest 2013; 143 (02) 461-470
33 Hunninghake GW. Release of interleukin-1 by alveolar macrophages of patients with active pulmonary sarcoidosis. Am Rev Respir Dis 1984; 129 (04) 569-572
34 Ruperto N, Brunner HI, Quartier P. , et al; PRINTO; PRCSG. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367 (25) 2396-2406
35 Alten R, Gomez-Reino J, Durez P. , et al. Efficacy and safety of the human anti-IL-1β monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study. BMC Musculoskelet Disord 2011; 12: 153
36 Ford HJ, Baughman RP, Aris R, Engel P, Donohue JF. Tadalafil therapy for sarcoidosis-associated pulmonary hypertension. Pulm Circ 2016; 6 (04) 557-562
37 Baughman RP, Drent M, Culver DA. , et al. Endpoints for clinical trials of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2012; 29 (02) 90-98
38 Moller DR. Negative clinical trials in sarcoidosis: failed therapies or flawed study design?. Eur Respir J 2014; 44 (05) 1123-1126